These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
328 related items for PubMed ID: 17482934
21. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Maru N, Ohori M, Kattan MW, Scardino PT, Wheeler TM. Hum Pathol; 2001 Aug; 32(8):828-33. PubMed ID: 11521227 [Abstract] [Full Text] [Related]
22. Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables. Ferrari MK, McNeal JE, Malhotra SM, Brooks JD. Urology; 2004 Oct; 64(4):749-53. PubMed ID: 15491714 [Abstract] [Full Text] [Related]
23. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. Rampersaud EN, Sun L, Moul JW, Madden J, Freedland SJ. J Urol; 2008 Aug; 180(2):571-6; discussion 576. PubMed ID: 18554662 [Abstract] [Full Text] [Related]
24. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. Jack GS, Cookson MS, Coffey CS, Vader V, Roberts RL, Chang SS, Smith JA, Shappell SB. J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301 [Abstract] [Full Text] [Related]
25. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA. Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298 [Abstract] [Full Text] [Related]
31. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ. J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888 [Abstract] [Full Text] [Related]
32. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML. J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342 [Abstract] [Full Text] [Related]
33. Should we replace the Gleason score with the amount of high-grade prostate cancer? Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH. Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413 [Abstract] [Full Text] [Related]
34. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. Dattoli M, Wallner K, True L, Cash J, Sorace R. Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673 [Abstract] [Full Text] [Related]
35. Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence. Poulos CK, Koch MO, Eble JN, Daggy JK, Cheng L. Cancer; 2004 Oct 01; 101(7):1563-8. PubMed ID: 15378493 [Abstract] [Full Text] [Related]
36. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Vis AN, Schröder FH, van der Kwast TH. Eur Urol; 2006 Aug 01; 50(2):258-65. PubMed ID: 16413660 [Abstract] [Full Text] [Related]
37. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG. J Urol; 2008 Nov 01; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539 [Abstract] [Full Text] [Related]